Abstract:Objectives Docosahexaenoic acid (DHA) is routinely recommended to adequate fetal development during gestation. Since it is a substance with intense anti‐inflammatory action, its effects upon the fetal heart and circulation are unknown and safety of its administration during gestation is not yet established. This randomized clinical trial was designed to investigate if maternal supplementation of DHA is followed by alterations of maternal prostaglandin levels and fetal ductus arteriosus flow dynamics, at the final trimester of pregnancy. Methods A double blind, placebo‐controlled, randomized clinical trial by parallel groups was designed. The study was developed in the period of 2018 to 2021. Pregnant women above 18 years of age, at 27 or 28 weeks without cardiac alterations at fetal echocardiography were enlisted to the trial, with exclusion of those taking substances with known prostaglandin inhibition effect, such as nonsteroidal anti‐inflammatory drugs and polyphenol‐rich foods. The intervention group received oral supplementation of omega‐3 with 450 mg/day of DHA, and the placebo group received capsules of soy lecithin. Both groups were supplemented for eight weeks. The following data were obtained at the beginning and at the end of the follow‐up: anthropometric, assessment of polyphenol and omega‐3 consumption, fetal morphological ultrasound, fetal Doppler echocardiographic examination and blood draw to assess prostaglandin levels. Participants were considered eligible, without cardiac or extracardiac abnormalities, when the diagnosis of ductal constriction was excluded by two observers. Intergroup and intragroup data were evaluated. Results The study ended up with 24 participants in each group. After 8 weeks, Doppler echocardiographic parameters of ductal flow and serum prostaglandin levels in both groups did not show significant intergroup differences. The expected intragroup differences as a result in increase in gestational ages were present. Conclusions Even though complete safety of DHA has not been tested, this randomized clinical trial shows that third trimester maternal supplementation of DHA, at the doses and period used, does not result in inhibition of PGE2 and does not cause ductus arteriosus constriction, providing the basis for post‐market surveillance studies with larger numbers, to allow the best clinical reassurance. This article is protected by copyright. All rights reserved.

The Influence of Prenatal DHA Supplementation on Individual Domains of Behavioral Functioning in School-Aged Children: Follow-Up of a Randomized Controlled Trial

Maternal high-dose docosahexaenoic acid supplementation and neurodevelopment at 5 Years of preterm children

DHA supplementation in infants born preterm and the effect on attention at 18 months' corrected age: follow-up of a subset of the N3RO randomised controlled trial

Maternal FADS2 single nucleotide polymorphism modified the impact of prenatal docosahexaenoic acid (DHA) supplementation on child neurodevelopment at 5 years: Follow-up of a randomized clinical trial

Could early life DHA supplementation benefit neurodevelopment? A systematic review and meta-analysis

Complexity of understanding the role of dietary and erythrocyte docosahexaenoic acid (DHA) on the cognitive performance of school-age children

Docosahexaenoic acid for reading, working memory and behavior in UK children aged 7-9: A randomized controlled trial for replication (the DOLAB II study)

Dietary DHA, bioaccessibility, and neurobehavioral development in children

Subgroup analyses of a randomized trial of DHA supplementation for infants born preterm with assessments of cognitive development up to 7-years of age: What happens in infants born <29 weeks' gestation?

Effects of prenatal docosahexaenoic acid supplementation on offspring cardiometabolic health at 11 years differs by maternal single nucleotide polymorphism rs174602: follow-up of a randomized controlled trial in Mexico

Impact of the n-6:n-3 long-chain PUFA ratio during pregnancy and lactation on offspring neurodevelopment: 5-year follow-up of a randomized controlled trial

Infant Metabolome in Relation to Prenatal DHA Supplementation and Maternal Single-Nucleotide Polymorphism rs174602: Secondary Analysis of a Randomized Controlled Trial in Mexico

DHA, nutrient intake, and maternal characteristics as predictors of pregnancy outcomes in a randomised clinical trial of DHA supplementation

Effect of n-3 PUFA supplementation on cognitive function throughout the life span from infancy to old age: a systematic review and meta-analysis of randomized controlled trials.

Effect of n 2 3 PUFA supplementation on cognitive function throughout the life span from infancy to old age : a systematic review and meta-analysis of randomized controlled trials 1 – 4

Maternal consumption of a docosahexaenoic acid-containing functional food during pregnancy: benefit for infant performance on problem-solving but not on recognition memory tasks at age 9 mo

Association Between Maternal Erythrocyte PUFAs During Pregnancy and Neurodevelopment in Children at 2 Years of Age: a Birth Cohort Study

No effect of 6-month supplementation with 300 mg/d docosahexaenoic acid on executive functions among healthy school-aged children: a randomized, double-blind, placebo-controlled trial

Maternal docosahexaenoic acid feeding protects against impairment of learning and memory and oxidative stress in prenatally stressed rats: possible role of neuronal mitochondria metabolism.

Reduction of the n-6:n-3 long-chain PUFA ratio during pregnancy and lactation on offspring body composition: follow-up results from a randomized controlled trial up to 5 y of age

Maternal supplementation of DHA does not cause fetal ductus arteriosus constriction: randomized controlled trial